Neurobiologically-based treatments in Rett syndrome: opportunities and challenges

References

• Hampson DR, Gholizadeh S, Pacey LK. Pathways to drug development for autism spectrum disorders. Clin Pharmacol Ther. 2012;91(2):189–200.
   PubMed Web of Science ®Google Scholar
• Wang H, Pati S, Pozzo-Miller L, et al. Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes. Front Cell Neurosci. 2015;9:55.
   PubMed Web of Science ®Google Scholar
• Gross C, Hoffmann A, Bassell GJ, et al. Therapeutic strategies in fragile X syndrome: from bench to bedside and back. Neurotherapeutics. 2015;12(3):584–608.
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Des Portes V, Hagerman R, et al. Mavoglurant in fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials. Sci Transl Med. 2016;8(321):321ra5.
   PubMed Web of Science ®Google Scholar
• Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68(6):944–950.
   PubMed Web of Science ®Google Scholar
• Gadalla KKE, Bailey MES, Cobb SR. MeCP2 and Rett syndrome: reversibility and potential avenues for therapy. Biochem J. 2011;439(1):1–14.
   PubMed Web of Science ®Google Scholar
• Pozzo-Miller L, Pati S, Percy AK. Rett syndrome: reaching for clinical trials. Neurotherapeutics. 2015;12(3):631–640.
   PubMed Web of Science ®Google Scholar
• Katz DM, Bird A, Coenraads M, et al. Rett syndrome: crossing the threshold to clinical translation. Trends Neurosci. 2016;39(2):100–113.
   PubMed Web of Science ®Google Scholar
• Rett A. [On an until now unknown disease of a congenital metabolic disorder]. Krankenschwester. 1966;19(9):121–122. German.
   PubMedGoogle Scholar
• Hagberg B, Aicardi J, Dias K, et al. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett’s syndrome: report of 35 cases. Ann Neurol. 1983;14(4):471–479.
   PubMed Web of Science ®Google Scholar
• Amir RE, Van Den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23(2):185–188.
   PubMed Web of Science ®Google Scholar
• Neul JL, Lane JB, Lee H-S, et al. Developmental delay in Rett syndrome: data from the natural history study. J Neurodev Disord. 2014;6(1):20.
   PubMed Web of Science ®Google Scholar
• Young DJ, Bebbington A, Anderson A, et al. The diagnosis of autism in a female: could it be Rett syndrome? Eur J Pediatr. 2008;167(6):661–669.
   PubMed Web of Science ®Google Scholar
• Humphreys P, Barrowman N. The incidence and evolution of parkinsonian rigidity in Rett syndrome: a pilot study. Can J Neurol Sci. 2016;43(4):567–573.
   PubMed Web of Science ®Google Scholar
• Carter P, Downs J, Bebbington A, et al. Stereotypical hand movements in 144 subjects with Rett syndrome from the population-based Australian database. Mov Disord. 2010;25(3):282–288.
   PubMed Web of Science ®Google Scholar
• Tarquinio DC, Motil KJ, Hou W, et al. Growth failure and outcome in Rett syndrome: specific growth references. Neurology. 2012;79(16):1653–1661.
   PubMed Web of Science ®Google Scholar
• Tarquinio DC, Hou W, Neul JL, et al. The changing face of survival in Rett syndrome and MECP2-related disorders. Pediatr Neurol. 2015;53(5):402–411.
   PubMed Web of Science ®Google Scholar
• Glaze DG, Percy AK, Skinner S, et al. Epilepsy and the natural history of Rett syndrome. Neurology. 2010;74(11):909–912.
   PubMed Web of Science ®Google Scholar
• Nissenkorn A, Levy-Drummer RS, Bondi O, et al. Epilepsy in Rett syndrome–lessons from the Rett networked database. Epilepsia. 2015;56(4):569–576.
   PubMed Web of Science ®Google Scholar
• Motil KJ, Caeg E, Barrish JO, et al. Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome. J Pediatr Gastroenterol Nutr. 2012;55(3):292–298.
   PubMed Web of Science ®Google Scholar
• Freilinger M, Böhm M, Lanator I, et al. Prevalence, clinical investigation, and management of gallbladder disease in Rett syndrome. Dev Med Child Neurol. 2014;56(8):756–762.
   PubMed Web of Science ®Google Scholar
• Downs J, Torode I, Wong K, et al. The natural history of scoliosis in females with Rett syndrome. Spine (Phila PA 1976). 2016;41(10):856–863.
   PubMed Web of Science ®Google Scholar
• Percy AK, Lee H-S, Neul JL, et al. Profiling scoliosis in Rett syndrome. Pediatr Res. 2010;67(4):435–439.
   PubMed Web of Science ®Google Scholar
• Jefferson A, Leonard H, Siafarikas A, et al. Clinical guidelines for management of bone health in Rett syndrome based on expert consensus and available evidence. PLoS One. 2016;11(2):e0146824.
   Google Scholar
• Khwaja OS, Ho E, Barnes KV, et al. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci U S A. 2014;111(12):4596–4601.
   PubMed Web of Science ®Google Scholar
• Barnes KV, Coughlin FR, O’Leary HM, et al. Anxiety-like behavior in Rett syndrome: characteristics and assessment by anxiety scales. J Neurodev Disord. 2015;7(1):30.
   PubMed Web of Science ®Google Scholar
• Kaufmann WE, Tierney E, Rohde CA, et al. Social impairments in Rett syndrome: characteristics and relationship with clinical severity. J Intellect Disabil Res. 2012;56(3):233–247.
   PubMed Web of Science ®Google Scholar
• Wandin H, Lindberg P, Sonnander K. Communication intervention in Rett syndrome: a survey of speech language pathologists in Swedish health services. Disabil Rehabil. 2015;37(15):1324–1333.
   PubMed Web of Science ®Google Scholar
• Lotan M. Assistive technology and supplementary treatment for individuals with Rett syndrome. ScientificWorldJournal. 2007;7:903–948.
   PubMed Web of Science ®Google Scholar
• Downs J, Bergman A, Carter P, et al. Guidelines for management of scoliosis in Rett syndrome patients based on expert consensus and clinical evidence. Spine (Phila PA 1976). 2009;34(17):E607–E617.
   Google Scholar
• Leonard H, Ravikumara M, Baikie G, et al. Assessment and management of nutrition and growth in Rett syndrome. J Pediatr Gastroenterol Nutr. 2013;57(4):451–460.
   PubMed Web of Science ®Google Scholar
• Baikie G, Ravikumara M, Downs J, et al. Gastrointestinal dysmotility in Rett syndrome. J Pediatr Gastroenterol Nutr. 2014;58(2):237–244.
   PubMed Web of Science ®Google Scholar
• Kaufmann WE. Cortical development in Rett syndrome: molecular, neurochemical, and anatomical aspects. In: Kerr A, Engerström IW, editors. The Rett disorder and the developing brain. Oxford: Oxford University Press; 2001. p. 85–110.
   Google Scholar
• Kaufmann WE, Johnston MV, Blue ME. MeCP2 expression and function during brain development: implications for Rett syndrome’s pathogenesis and clinical evolution. Brain Dev. 2005;27(Suppl 1):S77–S87.
   Google Scholar
• Blue ME, Kaufmann WE, Bressler J, et al. Temporal and regional alterations in NMDA receptor expression in Mecp2-null mice. Anat Rec (Hoboken). 2011;294(10):1624–1634.
   PubMedGoogle Scholar
• Blue ME, Naidu S, Johnston MV. Development of amino acid receptors in frontal cortex from girls with Rett syndrome. Ann Neurol. 1999;45(4):541–545.
   PubMed Web of Science ®Google Scholar
• Cuddapah VA, Pillai RB, Shekar KV, et al. Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome. J Med Genet. 2014;51(3):152–158.
   PubMed Web of Science ®Google Scholar
• Bebbington A, Anderson A, Ravine D, et al. Investigating genotype-phenotype relationships in Rett syndrome using an international data set. Neurology. 2008;70(11):868–875.
   PubMed Web of Science ®Google Scholar
• Christodoulou J, Weaving LS. MECP2 and beyond: phenotype-genotype correlations in Rett syndrome. J Child Neurol. 2003;18(10):669–674.
   PubMed Web of Science ®Google Scholar
• Gadalla KKE, Bailey MES, Spike RC, et al. Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. Mol Ther. 2013;21(1):18–30.
   PubMed Web of Science ®Google Scholar
• Lombardi LM, Baker SA, Zoghbi HY. MECP2 disorders: from the clinic to mice and back. J Clin Invest. 2015;125(8):2914–2923.
   PubMed Web of Science ®Google Scholar
• Bhatnagar S, Zhu X, Ou J, et al. Genetic and pharmacological reactivation of the mammalian inactive X chromosome. Proc Natl Acad Sci U S A. 2014;111(35):12591–12598.
   PubMed Web of Science ®Google Scholar
• Jiang J, Jing Y, Cost GJ, et al. Translating dosage compensation to trisomy 21. Nature. 2013;500(7462):296–300.
   PubMed Web of Science ®Google Scholar
• Armstrong DD. Neuropathology of Rett syndrome. J Child Neurol. 2005;20(9):747–753.
   PubMed Web of Science ®Google Scholar
• Kaufmann WE, Capone GT, Carter JC, et al. Genetic intellectual disability: neurobiological and clinical aspects. In: Accardo PJ, editor. Capute & Accardo’s neurodevelopmental disabilities in infancy and childhood. Baltimore (MD): Paul H. Brookes Publishing; 2008. p. 155–173.
   Google Scholar
• Valenti D, de Bari L, De Filippis B, et al. Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: an overview of Down syndrome, autism, Fragile X and Rett syndrome. Neurosci Biobehav Rev. 2014;46(Pt 2):202–217.
   PubMed Web of Science ®Google Scholar
• Filosa S, Pecorelli A, D’Espositoc M, et al. Exploring the possible link between MeCP2 and oxidative stress in Rett syndrome. Free Radic Biol Med. 2015;88(Pt A):81–90.
   PubMed Web of Science ®Google Scholar
• Lintas C, Sacco R, Persico AM. Genome-wide expression studies in autism spectrum disorder, Rett syndrome, and Down syndrome. Neurobiol Dis. 2012;45(1):57–68.
   PubMed Web of Science ®Google Scholar
• Carter JC, Lanham DC, Pham D, et al. Selective cerebral volume reduction in Rett syndrome: a multiple-approach MR imaging study. AJNR Am J Neuroradiol. 2008;29(3):436–441.
   PubMed Web of Science ®Google Scholar
• Zachariah RM, Olson CO, Ezeonwuka C, et al. Novel MeCP2 isoform-specific antibody reveals the endogenous MeCP2E1 expression in murine brain, primary neurons and astrocytes. PLoS One. 2012;7(11):e49763.
   Google Scholar
• Maezawa I, Swanberg S, Harvey D, et al. Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions. J Neurosci. 2009;29(16):5051–5061.
   PubMed Web of Science ®Google Scholar
• Williams EC, Zhong X, Mohamed A, et al. Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons. Hum Mol Genet. 2014;23(11):2968–2980.
   PubMed Web of Science ®Google Scholar
• Lioy DT, Garg SK, Monaghan CE, et al. A role for glia in the progression of Rett’s syndrome. Nature. 2011;475(7357):497–500.
   PubMed Web of Science ®Google Scholar
• Nguyen MVC, Felice CA, Du F, et al. Oligodendrocyte lineage cells contribute unique features to Rett syndrome neuropathology. J Neurosci. 2013;33(48):18764–18774.
   PubMed Web of Science ®Google Scholar
• Horská A, Farage L, Bibat G, et al. Brain metabolism in Rett syndrome: age, clinical, and genotype correlations. Ann Neurol. 2009;65(1):90–97.
   PubMed Web of Science ®Google Scholar
• Colantuoni C, Jeon OH, Hyder K, et al. Gene expression profiling in postmortem Rett syndrome brain: differential gene expression and patient classification. Neurobiol Dis. 2001;8(5):847–865.
   PubMed Web of Science ®Google Scholar
• Derecki NC, Cronk JC, Lu Z, et al. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature. 2012;484(7392):105–109.
   PubMed Web of Science ®Google Scholar
• Wang J, Wegener JE, Huang T-W, et al. Wild-type microglia do not reverse pathology in mouse models of Rett syndrome. Nature. 2015;521(7552):E1–4.
   PubMed Web of Science ®Google Scholar
• O’Driscoll CM, Kaufmann WE, Bressler JP. MeCP2 deficiency enhances glutamate release through NF-κB signaling in myeloid derived cells. J Neuroimmunol. 2013;265(1–2):61–67.
   PubMed Web of Science ®Google Scholar
• Jin L-W, Horiuchi M, Wulff H, et al. Dysregulation of glutamine transporter SNAT1 in Rett syndrome microglia: a mechanism for mitochondrial dysfunction and neurotoxicity. J Neurosci. 2015;35(6):2516–2529.
   PubMed Web of Science ®Google Scholar
• Cronk JC, Derecki NC, Ji E, et al. Methyl-CpG binding protein 2 regulates microglia and macrophage gene expression in response to inflammatory stimuli. Immunity. 2015;42(4):679–691.
   PubMed Web of Science ®Google Scholar
• O’Driscoll CM, Lima MP, Kaufmann WE, et al. Methyl CpG binding protein 2 deficiency enhances expression of inflammatory cytokines by sustaining NF-κB signaling in myeloid derived cells. J Neuroimmunol. 2015;283:23–29.
   PubMed Web of Science ®Google Scholar
• Wenk GL. Rett syndrome: neurobiological changes underlying specific symptoms. Prog Neurobiol. 1997;51(4):383–391.
   PubMed Web of Science ®Google Scholar
• Shahbazian MD, Antalffy B, Armstrong DL, et al. Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum Mol Genet. 2002;11(2):115–124.
   PubMed Web of Science ®Google Scholar
• Kaufmann WE, Capone GT, Clarke M, et al. Autism in genetic intellectual disability: insights into idiopathic autism. In: Zimmerman AW, editor. Autism: current theories and evidence. Totowa (NJ): Humana Press; 2008. p. 81–108.
   Google Scholar
• Chao H-T, Chen H, Samaco RC, et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature. 2010;468(7321):263–269.
   PubMed Web of Science ®Google Scholar
• He LJ, Liu N, Cheng TL, et al. Conditional deletion of Mecp2 in parvalbumin-expressing GABAergic cells results in the absence of critical period plasticity. Nat Commun. 2014;5:5036.
   PubMed Web of Science ®Google Scholar
• Abdala AP, Toward MA, Dutschmann M, et al. Deficiency of GABAergic synaptic inhibition in the Kölliker-Fuse area underlies respiratory dysrhythmia in a mouse model of Rett syndrome. J Physiol. 2016;594(1):223–237.
   PubMed Web of Science ®Google Scholar
• Krishnan K, Wang B-S, Lu J, et al. MeCP2 regulates the timing of critical period plasticity that shapes functional connectivity in primary visual cortex. Proc Natl Acad Sci U S A. 2015;112(34):E4782–E4791.
   Google Scholar
• Calfa G, Li W, Rutherford JM, et al. Excitation/inhibition imbalance and impaired synaptic inhibition in hippocampal area CA3 of Mecp2 knockout mice. Hippocampus. 2015;25(2):159–168.
   PubMed Web of Science ®Google Scholar
• Frye RE, Casanova MF, Fatemi SH, et al. Neuropathological mechanisms of seizures in autism spectrum disorder. Front Neurosci. 2016;10:192.
   PubMed Web of Science ®Google Scholar
• Ramirez J-M, Ward CS, Neul JL. Breathing challenges in Rett syndrome: lessons learned from humans and animal models. Respir Physiol Neurobiol. 2013;189(2):280–287.
   PubMed Web of Science ®Google Scholar
• Zhong W, Cui N, Jin X, et al. Methyl CpG binding protein 2 gene disruption augments tonic currents of γ-aminobutyric acid receptors in locus coeruleus neurons: impact on neuronal excitability and breathing. J Biol Chem. 2015;290(30):18400–18411.
   PubMed Web of Science ®Google Scholar
• Blue ME, Naidu S, Johnston MV. Altered development of glutamate and GABA receptors in the basal ganglia of girls with Rett syndrome. Exp Neurol. 1999;156(2):345–352.
   PubMed Web of Science ®Google Scholar
• Durand S, Patrizi A, Quast KB, et al. NMDA receptor regulation prevents regression of visual cortical function in the absence of Mecp2. Neuron. 2012;76(6):1078–1090.
   PubMed Web of Science ®Google Scholar
• Hamberger A, Gillberg C, Palm A, et al. Elevated CSF glutamate in Rett syndrome. Neuropediatrics. 1992;23(4):212–213.
   PubMed Web of Science ®Google Scholar
• Patrizi A, Picard N, Simon AJ, et al. Chronic administration of the N-methyl-D-aspartate receptor antagonist ketamine improves Rett syndrome phenotype. Biol Psychiatry. 2016;79(9):755–764.
   PubMed Web of Science ®Google Scholar
• Li W, Pozzo-Miller L. BDNF deregulation in Rett syndrome. Neuropharmacology. 2014;76(Pt C):737–746.
   PubMed Web of Science ®Google Scholar
• LeBlanc JJ, DeGregorio G, Centofante E, et al. Visual evoked potentials detect cortical processing deficits in Rett syndrome. Ann Neurol. 2015;78(5):775–786.
   PubMed Web of Science ®Google Scholar
• Freilinger M, Dunkler D, Lanator I, et al. Effects of creatine supplementation in Rett syndrome: a randomized, placebo-controlled trial. J Dev Behav Pediatr. 2011;32(6):454–460.
   PubMed Web of Science ®Google Scholar
• Edison Pharmaceuticals. Edison pharmaceuticals announces phase 2 positive clinical results for EPI-743 in Rett syndrome. 2014 [cited 2016 Jun 16]. Available from: http://edisonpharma.com/wp-content/files_mf/1409757666RettSyndromepressrelease140903.pdf
   Google Scholar
• Glaze DG, Percy AK, Motil KJ, et al. A study of the treatment of Rett syndrome with folate and betaine. J Child Neurol. 2009;24(5):551–556.
   PubMed Web of Science ®Google Scholar
• Hagebeuk EEO, Koelman JHTM, Duran M, et al. Clinical and electroencephalographic effects of folinic acid treatment in Rett syndrome patients. J Child Neurol. 2011;26(6):718–723.
   PubMed Web of Science ®Google Scholar
• Temudo T, Rios M, Prior C, et al. Evaluation of CSF neurotransmitters and folate in 25 patients with Rett disorder and effects of treatment. Brain Dev. 2009;31(1):46–51.
   PubMed Web of Science ®Google Scholar
• Ramaekers VT, Hansen SI, Holm J, et al. Reduced folate transport to the CNS in female Rett patients. Neurology. 2003;61(4):506–515.
   PubMed Web of Science ®Google Scholar
• Ormazabal A, Artuch R, Vilaseca MA, et al. Cerebrospinal fluid concentrations of folate, biogenic amines and pterins in Rett syndrome: treatment with folinic acid. Neuropediatrics. 2005;36(6):380–385.
   PubMed Web of Science ®Google Scholar
• Hagebeuk EEO, Duran M, Abeling NGGM, et al. S-adenosylmethionine and S-adenosylhomocysteine in plasma and cerebrospinal fluid in Rett syndrome and the effect of folinic acid supplementation. J Inherit Metab Dis. 2013;36(6):967–972.
   PubMed Web of Science ®Google Scholar
• Haas RH, Rice MA, Trauner DA, et al. Therapeutic effects of a ketogenic diet in Rett syndrome. Am J Med Genet Suppl. 1986;1:225–246.
   PubMedGoogle Scholar
• Ellaway C, Williams K, Leonard H, et al. Rett syndrome: randomized controlled trial of L-carnitine. J Child Neurol. 1999;14(3):162–167.
   PubMed Web of Science ®Google Scholar
• Percy AK, Glaze DG, Schultz RJ, et al. Rett syndrome: controlled study of an oral opiate antagonist, naltrexone. Ann Neurol. 1994;35(4):464–470.
   PubMed Web of Science ®Google Scholar
• Leoncini S, De Felice C, Signorini C, et al. Oxidative stress in Rett syndrome: natural history, genotype, and variants. Redox Rep. 2011;16(4):145–153.
   PubMed Web of Science ®Google Scholar
• Maffei S, De Felice C, Cannarile P, et al. Effects of ω-3 PUFAs supplementation on myocardial function and oxidative stress markers in typical Rett syndrome. Mediators Inflamm. 2014;2014:1–8.
   Web of Science ®Google Scholar
• Signorini C, De Felice C, Leoncini S, et al. Altered erythrocyte membrane fatty acid profile in typical Rett syndrome: effects of omega-3 polyunsaturated fatty acid supplementation. Prostaglandins Leukot Essent Fatty Acids. 2014;91(5):183–193.
   PubMed Web of Science ®Google Scholar
• Gorbachevskaya N, Bashina V, Gratchev V, et al. Cerebrolysin therapy in Rett syndrome: clinical and EEG mapping study. Brain Dev. 2001;23(Suppl 1):S90–3.
   Google Scholar
• Djukic A, Feldman J, Frey HP, et al. OP23 – 2759: pharmacological treatment of Rett syndrome with glatiramer acetate (Copaxone). Eur J Paediatr Neurol. 2015;19:S8.
   Google Scholar
• Pini G, Scusa MF, Congiu L, et al. IGF1 as a potential treatment for Rett syndrome: safety assessment in six Rett patients. Autism Res Treat. 2012;2012:679801.
   PubMedGoogle Scholar
• Neuren Pharmaceuticals Limited. Neuren’s NNZ-2566 successful in demonstrating clinical benefit in Rett syndrome Phase 2 trial. 2014 [cited 2016 Jun 16]. Available from: www.neurenpharma.com/IRM/PDF/1447/NeurensuccessfulinRettsyndromePhase2trial
   Google Scholar
• Zappella M, Genazzani A, Facchinetti F, et al. Bromocriptine in the Rett syndrome. Brain Dev. 1990;12(2):221–225.
   PubMed Web of Science ®Google Scholar
• Gupta SV, Ewen R, Bibat J, et al. Pharmacokinetics and preliminary assessment of efficacy of dextromethorphan for the treatment of Rett syndrome. Ann Neurol. 2014;76:S246.
   PubMed Web of Science ®Google Scholar
• Ellaway CJ, Peat J, Williams K, et al. Medium-term open label trial of L-carnitine in Rett syndrome. Brain Dev. 2001;23(Suppl 1):S85–9.
   Google Scholar
• Percy AK. Clinical trials and treatment prospects. Ment Retard Dev Disabil Res Rev. 2002;8(2):106–111.
   PubMedGoogle Scholar
• De Felice C, Signorini C, Durand T, et al. Partial rescue of Rett syndrome by ω-3 polyunsaturated fatty acids (PUFAs) oil. Genes Nutr. 2012;7(3):447–458.
   PubMed Web of Science ®Google Scholar
• Hagebeuk EE, Duran M, Koelman JH, et al. Folinic acid supplementation in Rett syndrome patients does not influence the course of the disease: a randomized study. J Child Neurol. 2012;27(3):304–309.
   PubMed Web of Science ®Google Scholar
• Deacon RMJ, Glass L, Snape M, et al. NNZ-2566, a novel analog of (1-3) IGF-1, as a potential therapeutic agent for fragile X syndrome. Neuromolecular Med. 2015;17(1):71–82.
   PubMed Web of Science ®Google Scholar
• Abdala APL, Dutschmann M, Bissonnette JM, et al. Correction of respiratory disorders in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A. 2010;107(42):18208–18213.
   PubMed Web of Science ®Google Scholar
• Volkmann RA, Fanger CM, Anderson DR, et al. MPX-004 and MPX-007: new pharmacological tools to study the physiology of NMDA receptors containing the GluN2A subunit. PLoS One. 2016;11(2):e0148129.
   PubMed Web of Science ®Google Scholar
• FitzGerald PM, Jankovic J, Percy AK. Rett syndrome and associated movement disorders. Mov Disord. 1990;5(3):195–202.
   PubMed Web of Science ®Google Scholar
• Neul JL, Fang P, Barrish J, et al. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology. 2008;70(16):1313–1321.
   PubMed Web of Science ®Google Scholar
• Kerr AM, Nomura Y, Armstrong D, et al. Guidelines for reporting clinical features in cases with MECP2 mutations. Brain Dev. 2001;23(4):208–211.
   PubMed Web of Science ®Google Scholar
• Carter AS, Volkmar FR, Sparrow SS, et al. The Vineland adaptive behavior scales: supplementary norms for individuals with autism. J Autism Dev Disord. 1998;28(4):287–302.
   PubMed Web of Science ®Google Scholar
• Burd L, Cook J, Randall T. The hand apraxia scale. Percept Mot Skills. 1990;70(1):219–224.
   PubMed Web of Science ®Google Scholar
• Mount RH, Charman T, Hastings RP, et al. The Rett syndrome behaviour questionnaire (RSBQ): refining the behavioural phenotype of Rett syndrome. J Child Psychol Psychiatry. 2002;43(8):1099–1110.
   PubMed Web of Science ®Google Scholar
• Neul JL, Glaze DG, Percy AK, et al. Improving treatment trial outcomes for Rett syndrome: the development of Rett-specific anchors for the clinical global impression scale. J Child Neurol. 2015;30(13):1743–1748.
   PubMed Web of Science ®Google Scholar
• Neuren Pharmaceuticals Limited. A safety study of NNZ-2566 in pediatric Rett syndrome. [ cited 2016 Jun 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT02715115
   Google Scholar
• Arnold LE, Vitiello B, McDougle C, et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry. 2003;42(12):1443–1450.
   PubMed Web of Science ®Google Scholar
• Glaze DG. Neurophysiology of Rett syndrome. J Child Neurol. 2005;20(9):740–746.
   PubMed Web of Science ®Google Scholar
• Pini G, Congiu L, Benincasa A, et al. Illness severity, social and cognitive ability, and EEG analysis of ten patients with Rett syndrome treated with mecasermin (recombinant human IGF-1). Autism Res Treat. 2016;2016:1–9.
   Google Scholar
• Kerr AM, Julu PO. Recent insights into hyperventilation from the study of Rett syndrome. Arch Dis Child. 1999;80(4):384–387.
   PubMed Web of Science ®Google Scholar
• Iber C, Ancoli-Israel S, Chesson AL Jr., et al. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. Westchester (IL): American Academy of Sleep Medicine; 2007.
   Google Scholar
• Msall ME. Measuring functional skills in preschool children at risk for neurodevelopmental disabilities. Ment Retard Dev Disabil Res Rev. 2005;11(3):263–273.
   PubMedGoogle Scholar
• Freeman JM, Vining EP, Cost S, et al. Does carnitine administration improve the symptoms attributed to anticonvulsant medications?: a double-blinded, crossover study. Pediatrics. 1994;93(6 Pt 1):893–895.
   PubMed Web of Science ®Google Scholar
• Pini G, Congiu L, Benincasa A, et al. Illness severity, social and cognitive ability, and EEG analysis of ten patients with Rett syndrome treated with mecasermin (recombinant human IGF-1). Autism Res Treat. 2016;2016:5073078.
   PubMedGoogle Scholar
• Berry-Kravis E, Hessl D, Abbeduto L, et al. Outcome measures for clinical trials in fragile X syndrome. J Dev Behav Pediatr. 2013;34(7):508–522.
   PubMed Web of Science ®Google Scholar
• Erickson CA, Ray B, Maloney B, et al. Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. J Psychiatr Res. 2014;59:220–228.
   PubMed Web of Science ®Google Scholar
• Landis SC, Amara SG, Asadullah K, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490(7419):187–191.
   PubMed Web of Science ®Google Scholar
• Katz DM, Berger-Sweeney JE, Eubanks JH, et al. Preclinical research in Rett syndrome: setting the foundation for translational success. Dis Model Mech. 2012;5(6):733–745.
   PubMed Web of Science ®Google Scholar
• Castro J, Garcia RI, Kwok S, et al. Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A. 2014;111(27):9941–9946.
   PubMed Web of Science ®Google Scholar
• Tropea D, Giacometti E, Wilson NR, et al. Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A. 2009;106(6):2029–2034.
   PubMed Web of Science ®Google Scholar
• Neuren Pharmaceuticals Limited. Neuren’s trofinetide successful in proof of concept Phase 2 clinical trial in Fragile X syndrome. 2015 [cited 2016 Jun 16]. Available from: http://www.neurenpharma.com/irm/PDF/1557/TrofinetidesuccessfulinPhase2trialinFragileX
   Google Scholar
• Tarquinio DC, Hou W, Neul JL, et al. Age of diagnosis in Rett syndrome: patterns of recognition among diagnosticians and risk factors for late diagnosis. Pediatr Neurol. 2015;52(6):585-91.e2.
   PubMed Web of Science ®Google Scholar
• McConachie H, Parr JR, Glod M, et al. Systematic review of tools to measure outcomes for young children with autism spectrum disorder. Health Technol Assess. 2015;19(41):1–506.
   PubMed Web of Science ®Google Scholar
• Maenner MJ, Smith LE, Hong J, et al. Evaluation of an activities of daily living scale for adolescents and adults with developmental disabilities. Disabil Health J. 2013;6(1):8–17.
   PubMed Web of Science ®Google Scholar
• Lane JB, Lee H-S, Smith LW, et al. Clinical severity and quality of life in children and adolescents with Rett syndrome. Neurology. 2011;77(20):1812–1818.
   PubMed Web of Science ®Google Scholar
• Killian JT Jr., Lane JB, Lee H-S, et al. Caretaker quality of life in Rett syndrome: disorder features and psychological predictors. Pediatr Neurol. 2016;58:67–74.
   PubMed Web of Science ®Google Scholar